Literature DB >> 20064972

Oxidation of apolipoprotein A-I by myeloperoxidase impairs the initial interactions with ABCA1 required for signaling and cholesterol export.

Baohai Shao1, Chongren Tang, Jay W Heinecke, John F Oram.   

Abstract

A key cardioprotective effect of high-density lipoprotein involves the interaction of its major protein, apolipoprotein A-I (apoA-I) with ATP-binding cassette transporter A1 (ABCA1), a macrophage cholesterol exporter. ApoA-I is thought to remove cholesterol from macrophages by a cascade of events. First it binds directly to ABCA1, activating signaling pathways, and then it binds to and solubilizes lipid domains generated by ABCA1. HDL isolated from human atherosclerotic lesions and blood of subjects with established coronary artery disease contains elevated levels of 3-chlorotyrosine and 3-nitrotyrosine, two characteristic products of myeloperoxidase (MPO), a heme protein secreted by macrophages. Here we show that chlorination (but not nitration) of apoA-I by the MPO pathway impairs its ability to interact directly with ABCA1, to activate the Janus kinase 2 signaling pathway, and to promote efflux of cellular cholesterol. In contrast, oxidation of apoA-I has little effect on its ability to stabilize ABCA1 protein or to solubilize phospholipids. Our results indicate that chlorination of apoA-I by the MPO pathway selectively inhibits two critical early events in cholesterol efflux: (1) the binding of apoA-I to ABCA1 and (2) the activation of a key signaling pathway. Therefore, oxidation of apoA-I in the artery wall by MPO-generated chlorinating intermediates may contribute to atherogenesis by impairing cholesterol efflux from macrophages.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20064972      PMCID: PMC2882738          DOI: 10.1194/jlr.M004085

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  53 in total

Review 1.  Efflux and atherosclerosis: the clinical and biochemical impact of variations in the ABCA1 gene.

Authors:  Roshni R Singaraja; Liam R Brunham; Henk Visscher; John J P Kastelein; Michael R Hayden
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-05-22       Impact factor: 8.311

2.  Cross-linking and lipid efflux properties of apoA-I mutants suggest direct association between apoA-I helices and ABCA1.

Authors:  Angeliki Chroni; Tong Liu; Michael L Fitzgerald; Mason W Freeman; Vassilis I Zannis
Journal:  Biochemistry       Date:  2004-02-24       Impact factor: 3.162

3.  ABCA1 redistributes membrane cholesterol independent of apolipoprotein interactions.

Authors:  Ashley M Vaughan; John F Oram
Journal:  J Lipid Res       Date:  2003-04-16       Impact factor: 5.922

4.  Myeloperoxidase produces nitrating oxidants in vivo.

Authors:  Joseph P Gaut; Jaeman Byun; Hung D Tran; Wendy M Lauber; James A Carroll; Richard S Hotchkiss; Abderrazzaq Belaaouaj; Jay W Heinecke
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

5.  Leukocyte ABCA1 controls susceptibility to atherosclerosis and macrophage recruitment into tissues.

Authors:  Miranda van Eck; I Sophie T Bos; Wolfgang E Kaminski; Evelyn Orsó; Gregor Rothe; Jaap Twisk; Alfred Böttcher; Edwin S Van Amersfoort; Trudy A Christiansen-Weber; Wai-Ping Fung-Leung; Theo J C Van Berkel; Gerd Schmitz
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-23       Impact factor: 11.205

Review 6.  ABCA1-deficient mice: insights into the role of monocyte lipid efflux in HDL formation and inflammation.

Authors:  Robert J Aiello; Dominique Brees; Omar L Francone
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-01-09       Impact factor: 8.311

7.  A PEST sequence in ABCA1 regulates degradation by calpain protease and stabilization of ABCA1 by apoA-I.

Authors:  Nan Wang; Wengen Chen; Patrick Linsel-Nitschke; Laurent O Martinez; Birgit Agerholm-Larsen; David L Silver; Alan R Tall
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

8.  Naturally occurring mutations in the largest extracellular loops of ABCA1 can disrupt its direct interaction with apolipoprotein A-I.

Authors:  Michael L Fitzgerald; Andrea L Morris; Jeongmi S Rhee; Lorna P Andersson; Armando J Mendez; Mason W Freeman
Journal:  J Biol Chem       Date:  2002-06-25       Impact factor: 5.157

9.  ABCA1 and amphipathic apolipoproteins form high-affinity molecular complexes required for cholesterol efflux.

Authors:  M L Fitzgerald; A L Morris; A Chroni; A J Mendez; V I Zannis; M W Freeman
Journal:  J Lipid Res       Date:  2003-11-16       Impact factor: 5.922

10.  Apolipoprotein A-I activates protein kinase C alpha signaling to phosphorylate and stabilize ATP binding cassette transporter A1 for the high density lipoprotein assembly.

Authors:  Yoshio Yamauchi; Michi Hayashi; Sumiko Abe-Dohmae; Shinji Yokoyama
Journal:  J Biol Chem       Date:  2003-09-02       Impact factor: 5.157

View more
  46 in total

Review 1.  Genetics of cholesterol efflux.

Authors:  Iulia Iatan; Aurélien Palmyre; Sarah Alrasheed; Isabelle Ruel; Jacques Genest
Journal:  Curr Atheroscler Rep       Date:  2012-06       Impact factor: 5.113

2.  HDL-apolipoprotein A-I exchange is independently associated with cholesterol efflux capacity.

Authors:  Mark S Borja; Kit F Ng; Angela Irwin; Jaekyoung Hong; Xing Wu; Daniel Isquith; Xue-Qiao Zhao; Bryan Prazen; Virginia Gildengorin; Michael N Oda; Tomáš Vaisar
Journal:  J Lipid Res       Date:  2015-08-07       Impact factor: 5.922

3.  Tyrosine-lipid peroxide adducts from radical termination: para coupling and intramolecular Diels-Alder cyclization.

Authors:  Roman Shchepin; Matias N Möller; Hye-young H Kim; Duane M Hatch; Silvina Bartesaghi; Balaraman Kalyanaraman; Rafael Radi; Ned A Porter
Journal:  J Am Chem Soc       Date:  2010-11-19       Impact factor: 15.419

Review 4.  Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein.

Authors:  Valentina Kon; Haichun Yang; Sergio Fazio
Journal:  Arch Med Res       Date:  2015-05-23       Impact factor: 2.235

5.  HDL from apoA1 transgenic mice expressing the 4WF isoform is resistant to oxidative loss of function.

Authors:  Stela Z Berisha; Greg Brubaker; Takhar Kasumov; Kimberly T Hung; Patricia M DiBello; Ying Huang; Ling Li; Belinda Willard; Katherine A Pollard; Laura E Nagy; Stanley L Hazen; Jonathan D Smith
Journal:  J Lipid Res       Date:  2015-01-05       Impact factor: 5.922

Review 6.  Tyrosine modifications in aging.

Authors:  Maria B Feeney; Christian Schöneich
Journal:  Antioxid Redox Signal       Date:  2012-05-14       Impact factor: 8.401

7.  Inflammatory remodeling of the HDL proteome impairs cholesterol efflux capacity.

Authors:  Tomáš Vaisar; Chongren Tang; Ilona Babenko; Patrick Hutchins; Jake Wimberger; Anthony F Suffredini; Jay W Heinecke
Journal:  J Lipid Res       Date:  2015-05-20       Impact factor: 5.922

Review 8.  Tyrosine-Nitrated Proteins: Proteomic and Bioanalytical Aspects.

Authors:  Carlos Batthyány; Silvina Bartesaghi; Mauricio Mastrogiovanni; Analía Lima; Verónica Demicheli; Rafael Radi
Journal:  Antioxid Redox Signal       Date:  2016-07-22       Impact factor: 8.401

9.  Site-specific 5-hydroxytryptophan incorporation into apolipoprotein A-I impairs cholesterol efflux activity and high-density lipoprotein biogenesis.

Authors:  Maryam Zamanian-Daryoush; Valentin Gogonea; Anthony J DiDonato; Jennifer A Buffa; Ibrahim Choucair; Bruce S Levison; Randall A Hughes; Andrew D Ellington; Ying Huang; Xinmin S Li; Joseph A DiDonato; Stanley L Hazen
Journal:  J Biol Chem       Date:  2020-02-25       Impact factor: 5.157

Review 10.  Dysfunctional HDL and atherosclerotic cardiovascular disease.

Authors:  Robert S Rosenson; H Bryan Brewer; Benjamin J Ansell; Philip Barter; M John Chapman; Jay W Heinecke; Anatol Kontush; Alan R Tall; Nancy R Webb
Journal:  Nat Rev Cardiol       Date:  2015-09-01       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.